首页> 美国卫生研究院文献>Medical Gas Research >The role of Volatile Anesthetics in Cardioprotection: a systematic review
【2h】

The role of Volatile Anesthetics in Cardioprotection: a systematic review

机译:挥发性麻醉药在心脏保护中的作用:系统综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This review evaluates the mechanism of volatile anesthetics as cardioprotective agents in both clinical and laboratory research and furthermore assesses possible cardiac side effects upon usage. Cardiac as well as non-cardiac surgery may evoke perioperative adverse events including: ischemia, diverse arrhythmias and reperfusion injury. As volatile anesthetics have cardiovascular effects that can lead to hypotension, clinicians may choose to administer alternative anesthetics to patients with coronary artery disease, particularly if the patient has severe preoperative ischemia or cardiovascular instability. Increasing preclinical evidence demonstrated that administration of inhaled anesthetics - before and during surgery - reduces the degree of ischemia and reperfusion injury to the heart. Recently, this preclinical data has been implemented clinically, and beneficial effects have been found in some studies of patients undergoing coronary artery bypass graft surgery. Administration of volatile anesthetic gases was protective for patients undergoing cardiac surgery through manipulation of the potassium ATP (KATP) channel, mitochondrial permeability transition pore (mPTP), reactive oxygen species (ROS) production, as well as through cytoprotective Akt and extracellular-signal kinases (ERK) pathways. However, as not all studies have demonstrated improved outcomes, the risks for undesirable hemodynamic effects must be weighed against the possible benefits of using volatile anesthetics as a means to provide cardiac protection in patients with coronary artery disease who are undergoing surgery.
机译:这篇综述评估了在临床和实验室研究中挥发性麻醉药作为心脏保护剂的机理,并进一步评估了使用后可能产生的心脏副作用。心脏手术和非心脏手术都可能引起围手术期不良事件,包括:缺血,各种心律不齐和再灌注损伤。由于挥发性麻醉药具有可导致低血压的心血管作用,因此临床医生可能会选择对冠心病患者使用其他麻醉药,尤其是在患者患有严重的术前局部缺血或心血管不稳定的情况下。越来越多的临床前证据表明,在术前和术中吸入麻醉药可降低心脏的缺血和再灌注程度。最近,该临床前数据已在临床上实施,并且在进行冠状动脉搭桥手术的患者的一些研究中已发现有益效果。通过控制钾ATP(KATP)通道,线粒体通透性过渡孔(mPTP),产生活性氧(ROS)以及通过细胞保护性Akt和细胞外信号激酶,挥发性麻醉气体的施用对进行心脏手术的患者具有保护作用(ERK)途径。但是,由于并非所有研究都显示出改善的结果,因此必须权衡使用不良麻醉药作为在接受手术的冠心病患者提供心脏保护的手段时可能产生的益处的不良血液动力学效应的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号